197 related articles for article (PubMed ID: 34346830)
1. Primary cutaneous indolent B-cell lymphomas - a retrospective multicenter analysis and a review of literature.
Olszewska-Szopa M; Sobas M; Laribi K; Bao Perez L; Drozd-Sokołowska J; Subocz E; Joks M; Zduniak K; Gajewska M; de Nalecz AK; Romejko-Jarosińska J; Kumiega B; Waszczuk-Gajda A; Wróbel T; Czyz A
Acta Oncol; 2021 Oct; 60(10):1361-1368. PubMed ID: 34346830
[No Abstract] [Full Text] [Related]
2. Primary cutaneous B-cell lymphomas: part II. Therapy and future directions.
Suárez AL; Querfeld C; Horwitz S; Pulitzer M; Moskowitz A; Myskowski PL
J Am Acad Dermatol; 2013 Sep; 69(3):343.e1-11; quiz 355-6. PubMed ID: 23957985
[TBL] [Abstract][Full Text] [Related]
3. Primary Cutaneous B-Cell Lymphoma: Management and Patterns of Recurrence at the Multimodality Cutaneous Lymphoma Clinic of The Ohio State University.
Haverkos B; Tyler K; Gru AA; Winardi FK; Frederickson J; Hastings J; Elkins C; Zhang X; Xu-Welliver M; Wong HK; Porcu P
Oncologist; 2015 Oct; 20(10):1161-6. PubMed ID: 26306900
[TBL] [Abstract][Full Text] [Related]
4. Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients.
Servitje O; Muniesa C; Benavente Y; Monsálvez V; Garcia-Muret MP; Gallardo F; Domingo-Domenech E; Lucas A; Climent F; Rodriguez-Peralto JL; Ortiz-Romero PL; Sandoval J; Pujol RM; Estrach MT
J Am Acad Dermatol; 2013 Sep; 69(3):357-65. PubMed ID: 23796549
[TBL] [Abstract][Full Text] [Related]
5. Radiation therapy in indolent primary cutaneous B cell lymphoma: a single institute experience.
De Felice F; Grapulin L; Pieroni A; Salerno F; D'Elia GM; Pulsoni A; Musio D; Tombolini V
Ann Hematol; 2018 Dec; 97(12):2411-2416. PubMed ID: 30094511
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of radiation therapy of indolent cutaneous B-cell lymphomas and literature review.
Gauci ML; Quero L; Ram-Wolff C; Guillerm S; M'Barek B; Lebbé C; Bagot M; Hennequin C
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1668-1673. PubMed ID: 29578630
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous B-cell lymphomas: 2019 update on diagnosis, risk stratification, and management.
Wilcox RA
Am J Hematol; 2018 Nov; 93(11):1427-1430. PubMed ID: 30039522
[TBL] [Abstract][Full Text] [Related]
8. A Descriptive Study of 103 Primary Cutaneous B-Cell Lymphomas: Clinical and Pathological Characteristics and Treatment from the Spanish Lymphoma Oncology Group (GOTEL).
Martínez-Banaclocha N; Martínez-Madueño F; Caballé B; Badia J; Blanes M; Bujanda DA; Calvo V; Gómez Codina J; Blanco CQ; Espinosa P; Lavernia J; Arroyo FRG; Risueño MG; Llorca C; Cumeras R; Pulla MP; Gumà J
Cancers (Basel); 2024 Mar; 16(5):. PubMed ID: 38473391
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous B-cell lymphomas: 2015 update on diagnosis, risk-stratification, and management.
Wilcox RA
Am J Hematol; 2015 Jan; 90(1):73-6. PubMed ID: 25535037
[TBL] [Abstract][Full Text] [Related]
10. Clinical features and treatment outcomes of primary cutaneous B-cell lymphoma: a single-center analysis in South Korea.
Kim MJ; Hong ME; Maeng CH; Jung HA; Hong JY; Choi MK; Kim SJ; Ko YH; Kim WS
Int J Hematol; 2015 Mar; 101(3):273-8. PubMed ID: 25552248
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous B-cell lymphomas: 2013 update on diagnosis, risk-stratification, and management.
Wilcox RA
Am J Hematol; 2013 Jan; 88(1):73-6. PubMed ID: 23379008
[TBL] [Abstract][Full Text] [Related]
12. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
13. Primary cutaneous B-cell lymphomas: recent advances in diagnosis and management.
Sokol L; Naghashpour M; Glass LF
Cancer Control; 2012 Jul; 19(3):236-44. PubMed ID: 22710899
[TBL] [Abstract][Full Text] [Related]
14. Primary cutaneous B-cell lymphomas - clinicopathological, prognostic and therapeutic characterisation of 54 cases according to the WHO-EORTC classification and the ISCL/EORTC TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome.
Golling P; Cozzio A; Dummer R; French L; Kempf W
Leuk Lymphoma; 2008 Jun; 49(6):1094-103. PubMed ID: 18569636
[TBL] [Abstract][Full Text] [Related]
15. De-escalated radiotherapy for indolent primary cutaneous B-cell lymphoma.
Oertel M; Elsayad K; Weishaupt C; Steinbrink K; Eich HT
Strahlenther Onkol; 2020 Feb; 196(2):126-131. PubMed ID: 31758232
[TBL] [Abstract][Full Text] [Related]
16. Observation of lymphadenopathy, systemic symptoms, and treatment in suspected indolent cutaneous B-cell lymphomas.
Puccio J; Huang Y; Viveiros MD; Reneau JC; Chung C; Spaccarelli N; Dulmage B
Arch Dermatol Res; 2024 May; 316(5):199. PubMed ID: 38775835
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous lymphomas: an update. Part 2: B-cell lymphomas and related conditions.
Kempf W; Kazakov DV; Mitteldorf C
Am J Dermatopathol; 2014 Mar; 36(3):197-208; quiz 209-10. PubMed ID: 24658377
[TBL] [Abstract][Full Text] [Related]
18. Treatment of Indolent Cutaneous B-Cell Lymphoma with Intralesional or Intravenous Rituximab.
Menzer C; Rendon A; Hassel JC
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230709
[TBL] [Abstract][Full Text] [Related]
19. Innovative Therapeutic Approaches in Primary Cutaneous B Cell Lymphoma.
Lang CCV; Ramelyte E; Dummer R
Front Oncol; 2020; 10():1163. PubMed ID: 32850331
[No Abstract] [Full Text] [Related]
20. Cutaneous B-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management.
Hristov AC; Tejasvi T; Wilcox RA
Am J Hematol; 2023 Aug; 98(8):1326-1332. PubMed ID: 37434388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
